Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses that earn reliable returns and trade at a sensible price. Biodexa is a clinical-stage biopharmaceutical company with 11 employees, developing Tolimidone in Phase II for Type 1 diabetes and MTX110 in Phase I for rare/orphan brain cancer. It has no established product revenue or profit in the supplied data. The FairStock Lynch category is none because there are only 0 years of filed results, while 3 are needed, so there is no track record to judge. As of the close on 2026-10-13, the price was $0.35 and market cap $2.3M. The FairStock calculations show P/B of 0.02, P/E of -0.01, ROE of -42.00%, ROCE of -40.11%, and D/E of 0.01. The negative P/E reflects losses, and the low debt is not enough to offset negative returns. More troubling are the Piotroski F-Score of 1/9 and Altman Z-Score of -11.38, which point to severe financial weakness and distress. The 52-week range of $0.34 to $44.70 shows how volatile and speculative the stock has been. A low P/B might tempt a statistical bargain hunter, but Graham would want a margin of safety backed by assets, earnings, or a proven competitive advantage. Here, the value depends almost entirely on clinical trial outcomes. There is no moat, no revenue growth figure, and no profit growth figure to underwrite. In my view, this is not a sound value investment; it is a binary scientific bet with a very weak financial profile.

In plain English: Biodexa Pharmaceuticals is a very small clinical-stage biotech with 11 employees, working on experimental treatments for rare diseases and Type 1 diabetes. The supplied data shows it is losing money, has weak financial health scores, and no revenue or profit growth figures to judge. The share price looks extremely low compared with its past range, but that mainly reflects deep losses and high risk, not a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer